TRINETRA › Sectors › Healthcare
Standard Engineering Technology Limited (SETL) — share price, P/E and fundamentals
Standard Engineering Technology Limited (NSE: SETL) closed at ₹395.85 on 30 Oct 2026, +127.1% over one year, against a 52-week range of ₹104.56 – ₹468.15.
In the quarter ended 30 Jun 2026 (consolidated, filed 6 Aug 2026) it reported revenue of ₹248 cr and net profit of ₹26 cr, a 10.6% net margin; revenue grew 43.1% and profit grew 26.5% year on year.
On four consecutive filed quarters its trailing P/E is 89.1; since 23 May 2025 its own P/E has ranged from 27.9 to 109.4 (median 49.4), and today's reading is higher than 94% of those 355 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 13.4%, ROCE 18.9%, debt-to-equity 0.07, Piotroski F-score 3 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 28% of 64 sector peers; PBT margin higher than 31% of 64 sector peers; ROE higher than 45% of 64 sector peers.
Key figures
| Last close | ₹395.85 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -1.7% / +186.4% / +127.1% |
| 52-week low – high | ₹104.56 – ₹468.15 |
| Market capitalisation | ₹7,897 cr |
| Trailing P/E | 89.1 |
| Price / book | 10.01 |
| EV / EBITDA | 53.9 |
| Earnings yield | 1.1% |
| TTM EPS | ₹4.44 |
| TTM net profit | ₹89 cr |
| Quarter revenue | ₹248 cr |
| Quarter net profit | ₹26 cr |
| Net margin | 10.6% |
| Revenue growth (YoY) | +43.1% |
| Profit growth (YoY) | +26.5% |
| Return on equity | 13.4% |
| ROCE | 18.9% |
| Debt / equity | 0.07 |
| Current ratio | 2.40 |
| Free cash flow | ₹-15 cr |
| Piotroski F-score | 3 / 9 |
| Average daily turnover (50 days) | ₹29.4 cr |
Against Healthcare peers
| Metric | SETL | Peer median | Percentile |
|---|---|---|---|
| Net margin | 10.64 | 12.89 | 28 |
| PBT margin | 14.55 | 17.68 | 31 |
| ROE | 13.36 | 13.87 | 45 |
| ROCE | 18.90 | 17.26 | 64 |
| Debt / equity | 0.07 | 0.11 | 44 |
| Cash conversion | 0.55 | 1.25 | 15 |
| Trailing P/E | 89.08 | 43.26 | 92 |
| P/B | 10.01 | 6.02 | 76 |
Questions
What is the P/E ratio of Standard Engineering Technology Limited?
Standard Engineering Technology Limited's trailing P/E is 89.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 23 May 2025 its P/E has ranged 27.9–109.4.
What were Standard Engineering Technology Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Standard Engineering Technology Limited reported revenue of ₹248 cr and net profit of ₹26 cr (consolidated), filed with the exchange on 6 Aug 2026.
What is Standard Engineering Technology Limited's ROE?
Return on equity is 13.4% based on the balance sheet dated 31 Mar 2026.
Does Standard Engineering Technology Limited have debt?
Debt-to-equity is 0.07 on the balance sheet dated 31 Mar 2026.
What is SETL's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SETL traded between ₹104.56 and ₹468.15.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.